3 recruiting, 1 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 3, Terminated 1 |
Follow Clear-cell metastatic renal cell carcinoma: new trials by email Literature Review of Clear-cell metastatic renal cell carcinoma trials Research Report on Clear-cell metastatic renal cell carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma Casdatifan, Cabozantinib, Placebo - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | Arcus Biosciences, Inc. | 720 | 2025-09-08 | 2026-10-26 |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial Cytoreductive Nephrectomy, Active Comparator - Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 364 | 2021-03-08 | 2026-10-08 |
| Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery sunitinib or pazopanib, Cytoreductive nephrectomy - Clear-cell Metastatic Renal Cell Carcinoma | Phase 3 | Terminated | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 13 | 2015-11-01 | 2018-11-14 |
Carcinoma, Renal Cell (2) · Kidney Neoplasms (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Urologic Diseases (3) · Urologic Neoplasms (3) · Adenocarcinoma (2) · Carcinoma (2) · Kidney Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2)
cabozantinib (2) · Axitinib (1) · CTLA-4 Antigen (1) · Hyaluronoglucosaminidase (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Specimen Handling (1) · Sunitinib (1) · lenvatinib (1) · pazopanib (1) · pembrolizumab (1)
SWOG Cancer Research Network (2) · Arcus Biosciences, Inc. (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1)
United States (3) · Italy (2) · Argentina (1) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Romania (1) · Singapore (1) · South Korea (1)
Giuseppe Procopio, MD (1) · Pedro Barata (1)
PMID 32203306, PMID 33742979, PMID 35310961, PMID 42246926
2015 (1), U10CA180888 (1)